戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  long-acting orally active inhibitors of the LTB4 receptor.
2 oxoETEs do not appear to operate through the LTB4 receptor.
3 s, is crucial for high binding affinity with LTB4 receptors.
4  been reported to be a key binding domain to LTB4 receptors.
5 ng domain for interaction with high-affinity LTB4 receptors.
6 ase or via antagonism of the leukotriene B4 (LTB4) receptor.
7 ts of the human cell surface leukotriene B4 (LTB4) receptor.
8 ould be targeted by inhibitors of the LTB(4)-LTB4 receptor 1 (BLT1) pathway as a novel therapeutic ap
9                      Chronic blockade of the LTB4 receptor 1 (BLT1) receptor with CP-105,696, reduced
10                                         When LTB4 receptor 1 (BLT1) receptors were blocked with CP-10
11                                              LTB4 receptor activation initiated a rapid decrease in P
12                RP517 binds to the neutrophil LTB4 receptor after intravenous injection.
13                                   A specific LTB4 receptor antagonist (CP-105, 696) inhibited CLP-ind
14 ice could be blocked by administration of an LTB4 receptor antagonist confirming the role of BLT1 in
15 ly inhibited by treatment with the selective LTB4 receptor antagonist CP-105,696 (ED50= 8.6 mg/kg ora
16        We evaluated the potent and selective LTB4 receptor antagonist CP-105696 in a murine heterotop
17 ffective in this regard as the pharmacologic LTB4 receptor antagonist, ONO 4057, and the blocking ant
18       These LX mimetics were as potent as an LTB4 receptor antagonist, yet results from microphysiome
19         99mTc-RP517 is a new leukotriene B4 (LTB4) receptor antagonist developed for imaging acute in
20 sed around the high-affinity leukotriene B4 (LTB4) receptor antagonist SB 201146 (1) led to the ident
21 rt describes the synthesis of a new class of LTB4 receptor antagonists containing [2-[methyl(2-phenet
22 ction and support the clinical evaluation of LTB4 receptor antagonists in human organ transplantation
23 ationship (SAR) studies of two new series of LTB4 receptor antagonists in which the phenyl ring of th
24  may have a role in graft rejection and that LTB4 receptor antagonists may be clinically useful in th
25  (BM-DCs) express functional leukotriene B4 (LTB4) receptors as observed in dose-dependent chemotaxis
26 o augmented by paracrine cross talk with the LTB4 receptor BLT1.
27 ) by neutrophils and their expression of the LTB4 receptor BLT1.
28  a purinoceptor (P2Y7) and a leukotriene B4 (LTB4) receptor (BLTR).
29  study demonstrates expression of functional LTB4 receptors, both BLT1 and BLT2, in murine and human
30 e reduced in mice lacking either 5-LO or the LTB4 receptor BTL1, and that macrophages from these mice
31 1B and PTEN, these effects being mediated by LTB4 receptor BTL1.
32 ophils and elicit chemotactic activity in an LTB4 receptor-dependent manner.
33 rophils and elicit chemotactic activity in a LTB4 receptor-dependent manner.
34  A and antagonism of TRPV1 receptors but not LTB4 receptors inhibited LTB4-induced inflammation.
35 plays high affinity for the human neutrophil LTB4 receptor (Ki = 0.78 nM), blocks LTB4-induced Ca2+ m
36 leukocytes indicated that they do not act as LTB4 receptor level antagonists.
37 osinophil recruitment in EAE is dependent on LTB4 receptor ligation and further reveal a previously u
38                            Inhibition of the LTB4 receptor Ltb4r1, through either genetic or pharmaco
39 kotrienes (LTs) or with an antagonist of the LTB4 receptor (LY223982) blocked the release of elastase
40 est that LTB4 or other potential ligands for LTB4 receptors may be important mediators of allograft r
41 e B6 mice, suggesting that expression of the LTB4 receptor on both activated autoreactive T cells and
42  leukotriene receptor-1 (BLT-1), the primary LTB4 receptor, partitioned to low density fractions, co-
43 f MIF or blockade of the MIF receptor and/or LTB4 receptor resulted in protection from LPS-induced AL
44 ngs indicate that this murine receptor is an LTB4 receptor that is highly expressed on activated leuk
45             The first potent leukotriene B4 (LTB4) receptor type 2 (BLT2) agonists, endogenous 12(S)-
46 directly inhibit LTB4 by phosphorylating the LTB4 receptor using beta adrenergic receptor kinase.
47                                  Blockade of LTB4-receptor with the selective antagonist, LTB4 dimeth